8-K: Acutus Medical Faces Delisting from Nasdaq After Failing to Meet Minimum Bid Price and Equity Requirements

Acutus Medical, Inc. has received notification from Nasdaq that it will be delisted due to non-compliance with minimum bid price and stockholders' equity requirements, with trading to be suspended on May 9, 2024.

Summary

• Acutus Medical received a delisting notice from Nasdaq on April 30, 2024, because it failed to regain compliance with the $1.00 minimum bid price requirement.
• The company also failed to meet the minimum stockholders' equity requirement of $2.5 million, or the alternatives of $35 million market value of listed securities or $500,000 net income from continuing operations.
• Acutus Medical's stock will be suspended from trading on the Nasdaq Capital Market on May 9, 2024.
• The company does not plan to appeal the delisting decision.
• Acutus Medical's shares will be traded on the OTC Pink Sheets, and the company will seek market makers to facilitate trading.

Sentiment

Score: 2

Explanation: The document indicates a significant negative event for the company, with delisting from Nasdaq and a move to the OTC Pink Sheets, which is generally viewed as a negative outcome for investors.

Positives

• Acutus Medical will seek to establish relationships with market makers to provide additional trading opportunities on the OTC Pink Sheets.

Negatives

• Acutus Medical failed to meet the minimum bid price requirement of $1.00 per share.
• The company also failed to meet the minimum stockholders' equity requirement of $2.5 million.
• The company's stock will be delisted from the Nasdaq Capital Market.
• There is no assurance that a market for the company's shares will develop on the OTC Pink Sheets.

Risks

• The delisting from Nasdaq could negatively impact investor confidence and the company's ability to raise capital.
• Trading on the OTC Pink Sheets may result in lower liquidity and higher volatility for the company's stock.
• There is a risk that a market for the company's shares may not develop on the OTC Pink Sheets.

Future Outlook

The company's stock will be traded on the OTC Pink Sheets, and the company will seek to establish relationships with market makers to provide additional trading opportunities.

Management Comments

• The company does not intend to submit a hearing request to appeal the delisting decision.

Industry Context

Delisting from a major exchange like Nasdaq can significantly impact a company's visibility and access to capital, often leading to increased scrutiny and challenges in attracting investors. This is a significant setback for Acutus Medical and highlights the challenges faced by companies that fail to meet listing requirements.

Comparison to Industry Standards

• Many companies in the medical device sector face challenges in maintaining compliance with exchange listing requirements, particularly during periods of financial difficulty or market volatility.
• Companies like BioCardia and Second Sight Medical Products have also faced delisting notices in the past due to similar issues, highlighting the competitive and challenging nature of the medical device industry.
• The minimum bid price and stockholders' equity requirements are standard for Nasdaq and other major exchanges, and failure to meet these requirements is a common reason for delisting.

Stakeholder Impact

• Shareholders will likely experience a decrease in the value of their investment due to the delisting.
• Employees may face uncertainty about the company's future.
• Customers and suppliers may have concerns about the company's long-term viability.

Next Steps

• Acutus Medical's stock will be suspended from trading on the Nasdaq Capital Market on May 9, 2024.
• The company will begin trading on the OTC Pink Sheets.
• Acutus Medical will seek to establish relationships with market makers to provide additional trading opportunities.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, stockholders equity, OTC Pink Sheets, trading suspension, compliance, Acutus Medical